Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies

Fiona Blows, Kristy Driver, Marjanka Schmidt, Annegien Broeks, Flora E van Leeuwen, Jelle Wesseling, Maggie Cheang, Karen Gelmon, Torsten Nielson, Carl Blomqvist, Paivi Heikkila, Tuomas Heikkinen, Heli Nevanlinna, Lars Akslen, Louis Begin, William Foulkes, Fergus Couch, Xianshu Wang, Vicky Cafourek, Janet OlsonLaura Baglietto, Graham Giles, Gianluca Severi, Catriona Ann McLean, Melissa Southey, Emad Rakha, Andrew Green, Ian Ellis, Mark Sherman, Jolanta Lissowska, William Anderson, Angela Cox, Malcolm Reed, Simon Cross, Elena Provenzano, Sarah-Jane Dawson, Alison Dunning, Manjeet Humphreys, Douglas Easton, Montserrat Garcia-Closas, Carlos Caldas, Paul Pharoah, David Huntsman

Research output: Contribution to journalArticleResearchpeer-review

555 Citations (Scopus)


Immunohistochemical markers are often used to classify breast cancer into subtypes that are biologically distinct and behave differently. The aim of this study was to estimate mortality for patients with the major subtypes of breast cancer as classified using five immunohistochemical markers, to investigate patterns of mortality over time, and to test for heterogeneity by subtype.
Original languageEnglish
Pages (from-to)1 - 12
Number of pages12
JournalPLoS Medicine
Issue number5
Publication statusPublished - 2010

Cite this